Stockscreener 앱 받기
5.67
1.62%
0.10
시간 외 거래:
5.68
0.010
+0.18%
전일 마감가:
$5.57
열려 있는:
$5.54
하루 거래량:
553.02K
Relative Volume:
0.53
시가총액:
$543.35M
수익:
-
순이익/손실:
$-75.43M
주가수익비율:
-4.6472
EPS:
-1.2201
순현금흐름:
$-72.75M
1주 성능:
+0.53%
1개월 성능:
+3.85%
6개월 성능:
-7.36%
1년 성능:
+240.96%
1일 변동 폭
$5.53
$5.71
1주일 범위
$5.42
$5.98
52주 변동 폭
$1.6604
$7.44
Zura Bio Ltd Stock (ZURA) Company Profile
명칭
Zura Bio Ltd
전화
858-247-0520
주소
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
5.67 | 533.77M | 0 | -75.43M | -72.75M | -1.2201 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-09 | 개시 | Wedbush | Outperform |
| 2024-11-04 | 개시 | Leerink Partners | Outperform |
| 2024-09-05 | 개시 | H.C. Wainwright | Neutral |
| 2024-05-03 | 개시 | Piper Sandler | Overweight |
| 2023-10-10 | 개시 | Ladenburg Thalmann | Buy |
| 2023-08-25 | 개시 | Oppenheimer | Outperform |
| 2023-06-22 | 개시 | Guggenheim | Buy |
| 2023-06-14 | 개시 | Chardan Capital Markets | Buy |
| 2023-05-24 | 개시 | Raymond James | Strong Buy |
모두보기
Zura Bio Ltd 주식(ZURA)의 최신 뉴스
Zura Bio updates corporate presentation; HS Phase 2 topline Q4 2026, SSc readout H1 2027, cash runway through 2028 - TradingView
ZURA (ZURA) insider Someit Sidhu plans 40,000-share sale after option exercise - Stock Titan
Zura Bio Ltd SEC Filing (Aug 13, 2026) - Stock Titan
Zura Bio Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Guggenheim raises Zura Bio stock price target on new drug indication - Investing.com
Zura Bio Submits Q2 2026 SEC Report Highlighting Financial and Operational Status - Kalkine Media
Zura Bio Q2 Results: EPS Misses Estimate as Losses Widen 23.53% YoY - scanx.trade
Zura Bio Limited Reports Q2 2026 Financial Results and Updates Investor Presentation in 8-K Filing - Kalkine Media
Form 8K Zura Bio Limited For: 11 August By Investing.com - Investing.com Nigeria
Zura Bio Ltd 2Q 2026: Net loss $(26.3)M, EPS $(0.21) — 10-Q Summary - TradingView
Financial update and recent changes drive Zura Bio performance - Traders Union
Zura Bio Completes Enrollment in 247-Participant Hidradenitis Study - Stock Titan
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates - Yahoo Finance
Zura Bio Ltd expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Zura Bio Ltd (ZURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Zura Bio (ZURA) Projected to Announce Earnings on Thursday - MarketBeat
Zura Bio Ltd (ZURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zura Bio Ltd (ZURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zura Bio Ltd (ZURA) Cash Flow - TradingKey
Zura Bio Ltd (ZURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zura Bio Ltd (ZURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ZURA|Zura Bio Ltd|Price:5.230|Chg%:-0.060 - TradingKey
Zura Bio Ltd (ZURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ZURA|Zura Bio Ltd|Price:5.240|Chg%:-0.140 - TradingKey
TradingKey - TradingKey
Marlyn Teresa Mathew Net Worth (2026) - GuruFocus
William Blair Starts Zura Bio (ZURA) at Outperform - Yahoo Finance
ZURA Initiated Coverage by William Blair -- Rating Set to Outper - GuruFocus
What's Going on With Zura Bio Stock Wednesday?Zura Bio (NASDAQ:ZURA) - Benzinga
Zura Bio navigates growth path amid biotech volatility - Ad-hoc-news.de
William Blair initiates Zura Bio stock with outperform rating By Investing.com - Investing.com Nigeria
William Blair initiates Zura Bio stock with outperform rating - Investing.com
William Blair Initiates Zura Bio(ZURA.US) With Buy Rating - Moomoo
Zura Bio stock. Company profile and listing context. - Ad-hoc-news.de
Wedbush reiterates Outperform on Zura Bio, maintains $15 target - scanx.trade
Zura Bio’s Tibulizumab: First Dual BAFF & IL-17 Bispecific Antibody for Complex Autoimmune Diseases, Advancing in Phase 2 Trials – Minichart - Minichart
Jessica Chen - White & Case LLP
Zura Bio updates corporate presentation; tibulizumab Phase 2 toplines, $225.6M cash (Mar 31, 2026) - TradingView
Zura Bio (NASDAQ: ZURA) furnishes updated corporate presentation for investors - Stock Titan
Guggenheim Maintains Zura Bio(ZURA.US) With Buy Rating, Maintains Target Price $15 - Moomoo
We're Hopeful That Zura Bio (NASDAQ:ZURA) Will Use Its Cash Wisely - simplywall.st
Zura Bio completes enrollment in tibulizumab trials By Investing.com - Investing.com South Africa
ZURA Financial Update: Cash Position and Operational Outlook - GuruFocus
Zura Bio completes Phase 2 trial enrollment for tibulizumab in hidradenitis suppurativa - Traders Union
Zura Bio clears enrollment targets in two Phase 2 studies, adds a third - Stock Titan
Zura Bio completes enrollment in TibuSHIELD Phase 2 HS trial - scanx.trade
Zura Bio (ZURA) VP details share, RSU and option holdings - Stock Titan
Zura Bio | 4: Statement of changes in beneficial ownership of securities-Director Jarrett Jennifer - Moomoo
Zura Bio (NASDAQ: ZURA) director receives grant of 51,000 share options - Stock Titan
Zura Bio (ZURA) director awarded 51,000 share options at $3.62 - Stock Titan
Zura Bio (ZURA) director receives grant of 51,000 stock options - Stock Titan
Zura Bio Ltd (ZURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.67%
0.04%
자본화:
|
볼륨(24시간):